Lipids and Atherosclerosis Unit, IMIBIC/Hospital Universitario Reina Sofía/Universidad de Córdoba and Ciber Fisiopatologia Obesidad y Nutricion, Instituto Salud Carlos III. Spain.
Reina Sofia University Hospital, Lipids and Atherosclerosis Research Unit. Avda. Menéndez Pidal, s/n. 14004 Córdoba. Spain.
Curr Pharm Des. 2017;23(22):3233-3238. doi: 10.2174/1381612823666170317144853.
Cardiovascular disease (CVD) continues to be the major cause of death in the developed countries. Moreover, the cardiovascular risk factors leading towards the development of CVD, mainly type 2 diabetes and obesity, are on the rise. The current preventive and therapeutic management, centred on the control of traditional risk factors, is clearly not enough to stop this pandemic. Therefore, the search for new biomarkers in CVD is a priority in most clinical research programs. Currently, interest in gut microbiota has peaked due to its association with cardiovascular and non-cardiovascular diseases. The present review considers the current situation regarding the influence of gut microbiota on CVD and particularly, its influence on the main traditional risk factors that lead to CVD, such as lipids, diabetes, hypertension and obesity.
心血管疾病（CVD）仍然是发达国家的主要死亡原因。此外，导致 CVD 发展的心血管危险因素，主要是 2 型糖尿病和肥胖，正在上升。目前以控制传统危险因素为中心的预防和治疗管理显然不足以阻止这一流行。因此，寻找 CVD 的新生物标志物是大多数临床研究计划的重点。目前，由于肠道微生物群与心血管和非心血管疾病的关联，人们对其的兴趣达到了顶峰。本综述考虑了肠道微生物群对 CVD 的影响，特别是对导致 CVD 的主要传统危险因素（如脂质、糖尿病、高血压和肥胖）的影响的现状。
